Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: I have said before

"Most of us became investors in this co. b/c of the patents."

Most certainly since it was the only thing going for PTSC after its microprossor days. The only thing we thought the BOD got right was the negotiation of a partnership with TPL, outside of the revolving CEO's and the endless M&A newsletter talk. I don't necessarily believe RG foresaw the current events though. He had no control of the MMP, the company had cash in hand, and his directive was to transform PTSC into a viable operation since the patents wouldn't last forever. If these patents wind up dying on the vine, and RG has all his ducks lined up, then the next step will be contract announcements and the growth of an actual business. If that should occur (getting to the necessary cap requirements), I can only see the next step as being a Crossflo spinoff to, in effect, reduce the OS and gain a Nasdaq listing. The extra shares that were approved and the buybacks (aside from the 27ish million Crossflo shares) would increase the company's base of control and PTSC as we know it, may end up as a comatose patient. The only other option that could exist is HP buying out the Crossflo operation.........IMO.........

Share
New Message
Please login to post a reply